Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PRMT5 function and targeting in cancer
Hyungsoo Kim, Ze’ev A. Ronai
Cell Stress (2020) Vol. 4, Iss. 8, pp. 199-215
Open Access | Times Cited: 164

Showing 1-25 of 164 citing articles:

Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
Kavanya Feustel, Gerald S. Falchook
Journal of Immunotherapy and Precision Oncology (2022) Vol. 5, Iss. 3, pp. 58-67
Open Access | Times Cited: 77
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D. Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2412-2431
Open Access | Times Cited: 74
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program
Ming Huang, Wen Dong, Ruihui Xie, et al.
Cancer Communications (2022) Vol. 42, Iss. 5, pp. 447-470
Open Access | Times Cited: 70
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration
Jordi Rodón, Hans Prenen, Adrian G. Sacher, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 17
PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis
Zhe Wang, Ruolei Li, Niuniu Hou, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006890-e006890
Open Access | Times Cited: 37
PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis
Anyi Liu, Chengxin Yu, Cheng Qiu, et al.
Oncogene (2023) Vol. 42, Iss. 19, pp. 1572-1584
Open Access | Times Cited: 31
Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance
Yihang Gao, Chongchong Feng, Jingru Ma, et al.
Biochemical Pharmacology (2024) Vol. 221, pp. 116048-116048
Closed Access | Times Cited: 8
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes, John Tatlock, Karen A. Maegley, et al.
Molecular Cancer Therapeutics (2021) Vol. 21, Iss. 1, pp. 3-15
Open Access | Times Cited: 50
The Structure and Functions of PRMT5 in Human Diseases
Aishat Motolani, Matthew Martin, Mengyao Sun, et al.
Life (2021) Vol. 11, Iss. 10, pp. 1074-1074
Open Access | Times Cited: 48
Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma
Yuhong Luo, Yuqing Gao, Weiwei Liu, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1932-1951
Open Access | Times Cited: 45
The Role of Protein Arginine Methyltransferases in DNA Damage Response
Charles Brobbey, Liu Liu, Shasha Yin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9780-9780
Open Access | Times Cited: 35
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression
Bing Yao, Sha Zhu, Xiyi Wei, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 31
Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors
Eunji Hong, Wojciech Barczak, Sujin Park, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 16
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
Jack Carter, Michael Hulse, Monisha Sivakumar, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 11, pp. 2233-2243
Open Access | Times Cited: 16
Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies
Deping Li, Xiaopeng Peng, Zhihao Hu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115982-115982
Closed Access | Times Cited: 16
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression
Jianchao Zhang, Xiaokai Fan, Yunfan Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 26
Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
Shuangjie Liu, Zhuonan Liu, Chiyuan Piao, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 23
BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Chi Yin, Min Wang, Yingzhao Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e005532-e005532
Open Access | Times Cited: 15
Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5
Ni Zhu, Zhi-Fu Guo, Kyosuke Kazama, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 12, pp. 2244-2255
Open Access | Times Cited: 15
PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1
Fei Xie, Han Zhang, Kongkai Zhu, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 14
Emerging Targets in Non-Small Cell Lung Cancer
Louisa Liu, Joshua Soler, Karen L. Reckamp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10046-10046
Open Access | Times Cited: 5
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications
Santiago Haase, Stephen V. Carney, María L. Varela, et al.
Trends in cancer (2024) Vol. 10, Iss. 12, pp. 1147-1160
Closed Access | Times Cited: 5
Substrate adaptors are flexible tethering modules that enhance substrate methylation by the arginine methyltransferase PRMT5
Cyrus Y Jin, Moritz Hunkeler, Kathleen M. Mulvaney, et al.
Journal of Biological Chemistry (2025), pp. 108165-108165
Closed Access
In silico protein structural analysis of PRMT5 and RUVBL1 mutations arising in human cancers
Majd Al-Marrawi, Ruben C. Petreaca, Renee A. Bouley
Cancer Genetics (2025)
Open Access
Page 1 - Next Page

Scroll to top